ClinicalTrials.gg
Not yet recruitingNCT06853691Updated Mar 3, 2025

The Effects of Glasses-Free 3D Training on Visual and Cognitive Function in Presbyopic Individuals

An interventional study of glasses-free 3D visual training in Presbyopia, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Study summary

This study aims to evaluate the effectiveness of glasses-free 3D visual training in improving visual function, visual comfort, and the application ability of visual functions in individuals with presbyopia. The research will assess changes in brain activity related to visual processing using Electroencephalogram(EEG)and Functional near-infrared spectroscopy(NIRS) before and after the training. By examining the impact of stereoscopic stimulation on the functional connectivity of brain regions, the study seeks to provide new insights into the rehabilitation of presbyopia and its underlying mechanisms. The goal is to offer a non-invasive and scientifically supported approach to improving presbyopia treatment, potentially advancing clinical practices and contributing to brain science and ophthalmology

Read the detailed description

Presbyopia is a manifestation of aging, and the prevalence of presbyopia increases with age. About 1.7 to 2 billion people in the world have presbyopia. According to the criteria proposed by Hofstetter in 1950, presbyopia symptoms begin to appear in different individuals from the age of 40, and complete presbyopia occurs at the age of 60. With the occurrence of presbyopia, there will be a series of accompanying diseases, such as the decrease of contrast sensitivity, leading to visual discomfort. Moreover, near work is difficult and even affects daily life.

Conventional ophthalmic analysis and intervention are sufficient. Although invasive correction methods can achieve satisfactory visual quality, there is a certain surgical risk. It is necessary to consider not only the patient's general condition, but also the follow-up care. Some monocular correction at the cost of binocular stereoscopic vision will cause the damage of depth perception and seriously affect stereoscopic vision. Non-invasive methods also have certain limitations, such as glasses correction will increase the risk of falls due to the surrounding jumping and swimming effects, the effect of drugs is temporary, and will cause a series of adverse reactions. The glasses-free 3D vision training equipment is simple to operate, easy to implement the training process, and the content is variable, and no other equipment is needed. Due to the popularity of video terminals, the prevalence of electronic device related asthenopia is also increasing. In order to explore the improvement of accommodation function and the relief of asthenopia after glasses-free 3D training, a randomized controlled trial was designed. The effects of this training on the central nervous system were analyzed by electroencephalogram (EEG) and near-infrared spectroscopy (fNIRS).

The aim of this study is to evaluate the improvement of visual function, application ability of visual function, and visual comfort in patients with presbyopia through the intervention of glasses-free 3D visual training, and to evaluate the functional changes of brain visual-related areas in patients with presbyopia before and after the training combined with EEG and NIRS. To explore the effects of stereoscopic stimulation on the functional connectivity of brain regions and different frequency bands. To explore the scientific nature and effectiveness of glasses-free 3D visual training in the rehabilitation of presbyopia, to provide a new theoretical basis and method for the clinical treatment of presbyopia, and to provide more information and clues for exploring the complex stereo vision imaging mechanism in the fields of brain science and ophthalmology.

02

Conditions studied

  • Presbyopia

Browse trials for

Keywords

  • Presbyopia
  • visual training
  • EEG
  • fNIRS
03

In context

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

This study's planned enrollment of 60 is close to the median of 61 across 276 interventional studies indexed under Presbyopia.

Browse Presbyopia studies →

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 164 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40-60 years old, both sexes;
  2. refractive error -6.0D to 5.0D, astigmatism \<2.0D, anisometropia \<4.0D;
  3. binocular corrected visual acuity \<0.2LogMAR;
  4. stereoscopic threshold ≤100 ';
  5. The subjects could understand the purpose of this study and sign the .

Exclusion criteria

Exclusion Criteria:

  1. after lens replacement; People with cataracts, which affect vision, have other eye conditions such that simultaneous vision is not possible;
  2. using any medication known to affect accommodative function or wearing orthokeratology lenses in the past 1 month;
  3. patients with severe systemic disease or severe mental illness;
  4. Other situations where the investigator considers that the subject should not participate in the study for safety reasons or the interests of the patient.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Trail group

    Conduct 15 minutes of naked-eye 3D vision training. Twice a day, five days a week.

    Other: glasses-free 3D visual training

  • No intervention
    Control groups

    The subjects watched ordinary 2D videos for 15 minutes each time, all under the same lighting conditions. This was done twice a day, five days a week.

Interventions

  • Otherglasses-free 3D visual training

    Trail group Conduct 15 minutes of naked-eye 3D vision training. Twice a day, five days a week. Control groups The subjects watched ordinary 2D videos for 15 minutes each time, all under the same lighting conditions. This was done twice a day, five days a week.

06

What researchers measure

Primary outcomes

  1. Amplitude of accommodation

    The push-up method combined with negative lens method was used. The measurements were completed by a comprehensive refractometer. It was performed according to the methods in Clinical Procedures for Ocular Examination 4th

    Time frame: Baseline and after 6 and 12 weeks of training

Secondary outcomes

  1. Asthenopia scale

    The asthenopia scale consisted of 2 self-assessment items (" Do you have symptoms of asthenopia "and" does eye fatigue affect your study, work or life ") and 19 symptom items (" Do you feel discomfort around the eyes ")

    Time frame: Baseline and after 6 and 12 weeks of training

  2. Vergence facility

    Vergence facility was tested using a lens flipper (3△BI/12△BO lens combination per eye) at 40cm with near correction

    Time frame: Baseline and after 6 and 12 weeks of training

  3. Accommodative convergence to accommodation(AC/A)

    Accommodative response was measured by WAM-5500. Additional accommodative and vergence stimuli were provided by spherical lenses

    Time frame: Baseline and after 6 and 12 weeks of training

  4. The node efficiency

    Electroencephalogram (EEG) was performed to track the electrical activity of the brain in real-time, and the node efficiency was calculated. Node efficiency is a metric that characterizes the efficiency of a single node in connecting with all other parts of the network. It reflects the centrality and importance of a node within the network.

    Time frame: Baseline and after 6 and 12 weeks of training

  5. Hemodynamic response functions

    Functional near-infrared spectroscopy (fNIRS) was conducted to capture spatial information on cerebral blood flow and oxygenation conditions. Therefore, a hemodynamic response function was constructed through it.

    Time frame: Baseline and after 6 and 12 weeks of training

  6. Convergence accommodation to convergence(CA/C)

    Accommodative response was measured by WAM-5500,Additional accommodative and vergence stimuli were provided by prisms

    Time frame: Baseline and after 6 and 12 weeks of training

  7. Functional connectivity network

    Electroencephalogram (EEG) was performed to track the electrical activity of the brain in real-time, and the functional connectivity network was calculated. Functional connectivity represent changes in brain activity in time domain and frequency domain respectively through correlation and coherence.

    Time frame: Baseline and after 6 and 12 weeks of training

  8. Negative relative vergence

    Negative relative vergence were measured by base in prism at 40cm with near correction

    Time frame: Baseline and after 6 and 12 weeks of training

  9. Positive relative vergence

    Positive relative vergence were measured by base out prism at 40cm with near correction

    Time frame: Baseline and after 6 and 12 weeks of training

Other outcomes

  1. Accommodative facility

    Accommodative facility was tested using a lens flipper (+0.5D/-0.5 D lens combination) at 1m with distance correction

    Time frame: Baseline and after 6 and 12 weeks of training

  2. Refraction and addition(near correction)

    In a semi-dark room, the Subjective Refraction and addition(ADD) measurements were performed. Thus, the subjects' near correction prescription were obtained

    Time frame: Baseline and after 6 and 12 weeks of training

  3. Near point of convergence

    Near point of convergence was measured using push-up method with near correction

    Time frame: Baseline and after 6 and 12 weeks of training

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2025, 10 months later.

Of 42 non-industry interventional studies with no phase under Presbyopia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's planned 10 months is below that.

Counting every sponsor, half of 129 studies reached it within 10 months; a quarter within 3 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Mar 3, 2025
StartEst.
Feb 27, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 1, 2026
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06853691
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Feb 27, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Mar 3, 2025

Study contacts

Yehong Zhuo, professor
Contact
zhuoyh@mail.sysu.edu.cn
020-66619349
Jinan Zhan
Contact
zhanjan@mail2.sysu.edu.cn
15015072151

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion